

Table SI. Baseline characteristics according to tertiles of WHR.

Variable	T ₁ (n=484)	T ₂ (n=486)	T ₃ (n=501)	P-value
Demographics				
Age, years (mean ± SD)	58.28±9.02	59.00±9.23	57.06±9.58	0.004
Male sex, n (%)	320 (66.12)	387 (79.63)	444 (88.62)	<0.001
Median BMI, kg/m ² (IQR)	25.35 (23.53, 27.64)	25.83 (23.92, 28.04)	26.03 (24.22, 27.99)	0.002
Risk factors, n (%)				
Cigarette smoking	244 (50.41)	291 (59.88)	363 (72.46)	<0.001
Diabetes	185 (38.22)	192 (39.51)	236 (47.11)	0.009
Hypertension	303 (62.66)	321 (66.05)	331 (66.07)	0.427
Dyslipidemia	477 (98.55)	483 (99.38)	498 (99.40)	0.272
Prior PCI	132 (27.27)	143 (29.42)	165 (32.93)	0.146
PAD	60 (12.40)	77 (15.84)	63 (12.57)	0.209
Clinical presentations				
Multi-vessel CAD, n (%)	387 (79.96)	395 (81.28)	407 (81.24)	0.838
Median LVEF, % (IQR)	65 (62, 66)	64 (60, 66)	64 (60, 66)	0.019
Laboratory measurements				
WBC, 10 ⁹ /l (mean ± SD)	5.43±1.12	6.58±1.14	8.03±1.60	<0.001
Neutrophil, 10 ⁹ /l (mean ± SD)	3.39±0.92	4.18±1.01	5.24±1.43	<0.001
Lymphocyte, 10 ⁹ /l (mean ± SD)	1.62±0.49	1.84±0.53	2.11±0.67	<0.001
Monocyte, 10 ⁹ /l (mean ± SD)	0.32±0.10	0.39±0.11	0.46±0.15	<0.001
TC, mmol/l (mean ± SD)	4.31±1.00	4.05±1.01	3.81±1.04	<0.001
LDL-C, mmol/l (mean ± SD)	2.52±0.87	2.41±0.82	2.30±0.85	<0.001
HDL-C, mmol/l (mean ± SD)	1.34±0.34	1.08±0.19	0.88±0.17	<0.001
Triglycerides, mmol/l (mean ± SD)	1.55±0.99	1.79±1.28	1.95±1.33	<0.001
HbA1c, % (mean ± SD)	6.24±1.07	6.35±1.22	6.54±1.28	<0.001
Median eGFR, ml/min per 1.73m ² (IQR)	110.97 (96.23, 124.09)	108.90 (96.26, 124.93)	113.50 (99.76, 127.20)	0.063
hs-CRP, mg/l (mean ± SD)	3.61±5.60	4.12±6.15	4.34±5.84	0.134
Medications at discharge, n (%)				
DAPT	483 (99.79)	485 (99.79)	500 (99.80)	0.100
Statins	473 (97.73)	475 (97.74)	493 (98.40)	0.689
ACEI/ARBs	211 (43.60)	247 (50.82)	278 (55.49)	<0.001
β-blockers	390 (80.58)	415 (85.39)	431 (86.03)	0.040
Angiographic findings				
Target vessel territory				
LM, n (%)	15 (3.10)	10 (2.06)	19 (3.79)	0.274
LAD, n (%)	286 (59.09)	278 (57.20)	260 (51.90)	0.061
LCX, n (%)	121 (25.00)	123 (25.31)	124 (24.75)	0.980
RCA, n (%)	169 (34.92)	188 (38.68)	207 (41.32)	0.116
Restenotic lesions, n (%)	28 (5.79)	22 (4.53)	30 (5.99)	0.551
Trifurcation/bifurcation lesions, n (%)	278 (57.44)	262 (53.91)	261 (52.10)	0.232
Lesions>20 mm long, n (%)	318 (65.70)	353 (72.63)	367 (73.25)	0.016
Median number of stents (IQR)	2 (1, 2)	2 (1, 2)	2 (1, 2)	0.373
Median length of stent, mm (IQR)	29 (18, 45)	33 (22, 48)	32 (21, 50)	0.066
TIMI grade 0/1, n (%)	73 (15.08)	88 (18.11)	102 (20.36)	0.096

ACEI, angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blockers; BMI, body mass index; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein-cholesterol; HbA1c, glycated hemoglobin A1c; hs-CRP, hypersensitive C-reactive protein; IQR, interquartile range; LVEF, left ventricular ejection fraction; LDL-C, low-density lipoprotein-cholesterol; LM, left main coronary artery; LAD, left anterior descending coronary artery; LCX, left circumflex branch; PCI, percutaneous coronary intervention; PAD, peripheral arterial disease; RCA, right coronary artery; TC, total cholesterol; TIMI, thrombolysis in myocardial infarction; WBC, white blood cell; WHR, WBC-to-HDL ratio.

Table SII. Baseline characteristics according to tertiles of MHR.

Variable	T ₁ (n=458)	T ₂ (n=512)	T ₃ (n=501)	P-value
Demographics				
Age, years (mean± SD)	58.23±8.85	58.04±8.98	58.05±10.04	0.939
Male sex, n (%)	280 (61.14)	420 (82.03)	451 (90.02)	<0.001
Median BMI, kg/m ² (IQR)	25.35 (23.44, 27.45)	25.95 (24.11, 28.03)	26.04 (24.22, 28.09)	<0.001
Risk factors, n (%)				
Cigarette smoking	210 (45.85)	323 (63.09)	365 (72.85)	<0.001
Diabetes	183 (39.96)	215 (41.99)	215 (42.91)	0.640
Hypertension	286 (62.45)	339 (66.21)	330 (65.87)	0.406
Dyslipidemia	455 (99.34)	505 (98.63)	498 (99.40)	0.349
Prior PCI	127 (27.73)	160 (31.25)	153 (30.54)	0.456
PAD	50 (10.92)	77 (15.04)	73 (14.57)	0.128
Clinical presentations				
Multi-vessel CAD, n (%)	365 (79.69)	417 (81.45)	407 (81.24)	0.756
Median LVEF, % (IQR)	64 (61, 66)	64 (61, 66)	63 (60, 65)	0.009
Laboratory measurements				
WBC, 10 ⁹ /l (mean ± SD)	5.80±1.39	6.59±1.43	7.62±1.72	<0.001
Neutrophil, 10 ⁹ /l (mean ± SD)	3.71±1.21	4.21±1.22	4.87±1.44	<0.001
Lymphocyte, 10 ⁹ /l (mean ± SD)	1.68±0.52	1.86±0.57	2.03±0.66	<0.001
Monocyte, 10 ⁹ /l (mean ± SD)	0.28±0.07	0.37±0.07	0.50±0.13	<0.001
TC, mmol/l (mean ± SD)	4.35±1.02	4.04±1.00	3.81±1.04	<0.001
LDL-C, mmol/l (mean ± SD)	2.54±0.88	2.41±0.81	2.29±0.85	<0.001
HDL-C, mmol/l (mean ± SD)	1.34±0.34	1.08±0.21	0.90±0.18	<0.001
Triglycerides, mmol/l (mean ± SD)	1.55±0.95	1.77±1.17	1.96±1.45	<0.001
HbA1c, % (mean ± SD)	6.26±1.09	6.37±1.22	6.49±1.27	0.013
Median eGFR, ml/min per 1.73m ² (IQR)	111.09 (98.37, 123.74)	110.11 (96.99, 125.06)	111.76 (96.69, 127.49)	0.714
hs-CRP, mg/l (mean ± SD)	3.62±5.17	4.26±6.61	4.16±5.66	0.197
Medications at discharge, n (%)				
DAPT	457 (99.78)	512 (100.00)	499 (99.60)	0.370
Statins	449 (98.03)	501 (97.85)	491 (98.00)	0.976
ACEI/ARBs	203 (44.32)	256 (50.00)	277 (55.29)	0.003
β-blockers	377 (82.31)	425 (83.01)	434 (86.63)	0.141
Angiographic findings				
Target vessel territory				
LM, n (%)	12 (2.62)	15 (2.93)	17 (3.39)	0.778
LAD, n (%)	276 (60.26)	294 (57.42)	254 (50.70)	0.009
LCX, n (%)	107 (23.36)	128 (25.00)	133 (26.55)	0.524
RCA, n (%)	168 (36.68)	194 (37.89)	202 (40.32)	0.495
Restenotic lesions, n (%)	20 (4.37)	31 (6.05)	29 (5.79)	0.468
Trifurcation/bifurcation lesions, n (%)	249 (54.37)	283 (55.27)	269 (53.69)	0.879
Lesions>20 mm long, n (%)	309 (67.47)	364 (71.09)	365 (72.85)	0.178
Median number of stents (IQR)	2 (1, 2)	2 (1, 2)	2 (1, 2)	0.263
Median length of stent, mm (IQR)	29 (20, 45)	33 (22, 49)	32 (21, 50)	0.183
TIMI grade 0/1, n (%)	73 (15.94)	92 (17.97)	98 (19.56)	0.343

ACEI, angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blockers; BMI, body mass index; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein-cholesterol; HbA1c, glycated hemoglobin A1c; hs-CRP, hypersensitive C-reactive protein; IQR, interquartile range; LVEF, left ventricular ejection fraction; LDL-C, low-density lipoprotein-cholesterol; LM, left main coronary artery; LAD, left anterior descending coronary artery; LCX, left circumflex branch; MHR, monocyte-to-HDL ratio; PCI, percutaneous coronary intervention; PAD, peripheral arterial disease; RCA, right coronary artery; TC, total cholesterol; TIMI, thrombolysis in myocardial infarction.

Table SIII. Baseline characteristics according to tertiles of LHR.

Variable	T ₁ (n=485)	T ₂ (n=485)	T ₃ (n=501)	P-value
Demographics				
Age, years (mean ± SD)	59.45±9.05	58.20±9.16	56.71±9.53	<0.001
Male sex, n (%)	343 (70.72)	387 (79.79)	421 (84.03)	<0.001
Median BMI, kg/m ² (IQR)	25.22 (23.44, 27.41)	25.83 (24.06, 27.77)	26.12 (24.31, 28.37)	<0.001
Risk factors, n (%)				
Cigarette smoking	245 (50.52)	305 (62.89)	348 (69.46)	<0.001
Diabetes	181 (37.32)	203 (41.86)	229 (45.71)	0.028
Hypertension	323 (66.60)	305 (62.89)	327 (65.27)	0.471
Dyslipidemia	482 (99.38)	476 (98.14)	500 (99.80)	0.016
Prior PCI	139 (28.66)	150 (30.93)	151 (30.14)	0.736
PAD	66 (13.61)	73 (15.05)	61 (12.18)	0.420
Clinical presentations				
Multi-vessel CAD, n (%)	382 (78.76)	402 (82.89)	405 (80.84)	0.264
Median LVEF, % (IQR)	65 (62, 66)	64 (60, 66)	64 (60, 66)	0.107
Laboratory measurements				
WBC, 10 ⁹ /l (mean ± SD)	5.93±1.52	6.62±1.45	7.51±1.70	<0.001
Neutrophil, 10 ⁹ /l (mean ± SD)	4.06±1.41	4.26±1.28	4.51±1.40	<0.001
Lymphocyte, 10 ⁹ /l (mean ± SD)	1.38±0.35	1.82±0.38	2.37±0.58	<0.001
Monocyte, 10 ⁹ /l (mean ± SD)	0.34±0.12	0.39±0.12	0.43±0.15	<0.001
TC, mmol/l (mean ± SD)	4.25±1.06	4.04±0.98	3.88±1.05	<0.001
LDL-C, mmol/l (mean ± SD)	2.49±0.88	2.41±0.79	2.33±0.87	0.015
HDL-C, mmol/l (mean ± SD)	1.31±0.35	1.09±0.22	0.90±0.19	<0.001
Triglycerides, mmol/l (mean ± SD)	1.56±1.02	1.75±1.15	1.97±1.43	<0.001
HbA1c, % (mean ± SD)	6.21±1.081	6.41±1.19	6.51±1.30	<0.001
Median eGFR, ml/min per 1.73m ² (IQR)	111.40 (95.83, 124.85)	110.12 (97.80, 125.57)	111.08 (98.75, 125.83)	0.720
hs-CRP, mg/l (mean ± SD)	3.79±6.37	3.83±5.26	4.44±5.92	0.147
Medications at discharge, n (%)				
DAPT	483 (99.59)	485 (100.00)	500 (99.80)	0.363
Statins	474 (97.73)	475 (97.94)	492 (98.20)	0.871
ACEI/ARBs	213 (43.92)	247 (50.93)	276 (55.09)	0.002
β-blockers	401 (82.68)	404 (83.30)	431 (86.03)	0.310
Angiographic findings				
Target vessel territory				
LM, n (%)	12 (2.47)	20 (4.12)	12 (2.40)	0.202
LAD, n (%)	286 (58.97)	268 (55.26)	270 (53.89)	0.253
LCX, n (%)	121 (24.95)	116 (23.92)	131 (26.15)	0.721
RCA, n (%)	178 (36.70)	190 (39.18)	196 (39.12)	0.662
Restenotic lesions, n (%)	23 (4.74)	27 (5.57)	30 (5.99)	0.682
Trifurcation/bifurcation lesions, n (%)	279 (57.53)	244 (50.31)	278 (55.49)	0.067
Lesions>20 mm long, n (%)	319 (65.77)	359 (74.02)	360 (71.86)	0.014
Median number of stents (IQR)	2 (1, 2)	2 (1, 2)	2 (1, 2)	0.132
Median length of stent, mm (IQR)	29 (18, 43)	33 (22, 47)	33 (21, 50)	0.024
TIMI grade 0/1, n (%)	87 (17.94)	80 (16.49)	96 (19.16)	0.550

ACEI, angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blockers; BMI, body mass index; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein-cholesterol; HbA1c, glycated hemoglobin A1c; hs-CRP, hypersensitive C-reactive protein; IQR, interquartile range; LVEF, left ventricular ejection fraction; LDL-C, low-density lipoprotein-cholesterol; LM, left main coronary artery; LAD, left anterior descending coronary artery; LCX, left circumflex branch; LHR, lymphocyte-to-HDL ratio; PCI, percutaneous coronary intervention; PAD, peripheral arterial disease; RCA, right coronary artery; TC, total cholesterol; TIMI, thrombolysis in myocardial infarction; WBC, white blood cell.

Table SIV. Baseline characteristics according to tertiles of NHR.

Variable	T ₁ (n=482)	T ₂ (n=487)	T ₃ (n=502)	P-value
Demographics				
Age, years (mean ± SD)	58.15±8.90	58.59±9.35	57.59±9.64	0.233
Male sex, n (%)	330 (68.46)	378 (77.62)	443 (88.25)	<0.001
Median BMI, kg/m ² (IQR)	25.39 (23.46, 27.78)	25.82 (24.06, 27.78)	25.97 (24.22, 27.81)	0.018
Risk factors, n (%)				
Cigarette smoking	251 (52.07)	294 (60.37)	353 (70.32)	<0.001
Diabetes	178 (36.93)	210 (43.12)	225 (44.82)	0.031
Hypertension	303 (62.86)	317 (65.09)	335 (66.73)	0.443
Dyslipidemia	478 (99.17)	482 (98.97)	498 (99.20)	0.917
Prior PCI	128 (26.56)	150 (30.80)	162 (32.27)	0.128
PAD	63 (13.07)	67 (13.76)	70 (13.94)	0.916
Clinical presentations				
Multi-vessel CAD, n (%)	388 (80.50)	390 (80.08)	411 (81.87)	0.755
Median LVEF, % (IQR)	65 (62, 66)	64 (60, 66)	64 (60, 66)	0.008
Laboratory measurements				
WBC, 10 ⁹ /l (mean ± SD)	5.43±1.08	6.57±1.14	8.04±1.62	<0.001
Neutrophil, 10 ⁹ /l (mean ± SD)	3.17±0.72	4.15±0.84	5.47±1.33	<0.001
Lymphocyte, 10 ⁹ /l (mean ± SD)	1.76±0.54	1.88±0.62	1.94±0.64	<0.001
Monocyte, 10 ⁹ /l (mean ± SD)	0.32±0.10	0.39±0.12	0.46±0.15	<0.001
TC, mmol/l (mean ± SD)	4.29±0.99	4.04±1.02	3.85±1.06	<0.001
LDL-C, mmol/l (mean ± SD)	2.51±0.83	2.41±0.86	2.31±0.85	0.002
HDL-C, mmol/l (mean ± SD)	1.31±0.35	1.08±0.21	0.91±0.20	<0.001
Triglycerides, mmol/l (mean ± SD)	1.61±1.10	1.71±1.09	1.96±1.42	<0.001
HbA1c, % (mean ± SD)	6.26±1.12	6.37±1.15	6.50±1.31	0.009
Median eGFR, ml/min per 1.73m ² (IQR)	111.69 (97.67, 125.71)	107.97 (94.36, 123.05)	112.93 (99.89, 127.15)	0.006
hs-CRP, mg/l (mean ± SD)	3.85±5.88	3.88±5.79	4.33±5.94	0.355
Medications at discharge, n (%)				
DAPT	481 (99.79)	487 (100.00)	500 (99.60)	0.381
Statins	471 (97.72)	478 (98.15)	492 (98.01)	0.888
ACEI/ARBs	212 (43.98)	250 (51.33)	274 (54.58)	0.003
β-blockers	389 (80.71)	410 (84.19)	437 (87.05)	0.025
Angiographic findings				
Target vessel territory				
LM, n (%)	12 (2.49)	12 (2.46)	20 (3.98)	0.274
LAD, n (%)	283 (58.71)	272 (55.85)	269 (53.59)	0.268
LCX, n (%)	122 (25.31)	121 (24.85)	125 (24.90)	0.983
RCA, n (%)	172 (35.68)	192 (39.43)	200 (39.84)	0.340
Restenotic lesions, n (%)	25 (5.19)	29 (5.95)	26 (5.18)	0.828
Trifurcation/bifurcation lesions, n (%)	269 (55.81)	272 (55.85)	260 (51.79)	0.337
Lesions>20 mm long, n (%)	318 (65.98)	352 (72.28)	368 (73.31)	0.025
Median number of stents (IQR)	2 (1, 2)	2 (1, 2)	2 (1, 2)	0.453
Median length of stent, mm (IQR)	29 (18, 47)	32 (22, 45)	32 (21, 50)	0.324
TIMI grade 0/1, n (%)	78 (16.18)	82 (16.84)	103 (20.52)	0.158

ACEI, angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blockers; BMI, body mass index; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein-cholesterol; HbA1c, glycated hemoglobin A1c; hs-CRP, hypersensitive C-reactive protein; IQR, interquartile range; LVEF, left ventricular ejection fraction; LDL-C, low-density lipoprotein-cholesterol; LM, left main coronary artery; LAD, left anterior descending coronary artery; LCX, left circumflex branch; NHR, neutrophil-to-HDL ratio; PCI, percutaneous coronary intervention; PAD, peripheral arterial disease; RCA, right coronary artery; TC, total cholesterol; TIMI, thrombolysis in myocardial infarction; WBC, white blood cell.

Table SV. Baseline characteristics according to tertiles of CHR.

Variable	T ₁ (n=481)	T ₂ (n=490)	T ₃ (n=500)	P-value
Demographics				
Age, years (mean ± SD)	57.87±9.62	58.05±9.49	58.39±8.82	0.670
Male sex, n (%)	371 (77.13)	388 (79.18)	392 (78.40)	0.737
Median BMI, kg/m ² (IQR)	25.71 (23.83, 27.68)	25.78 (24.11, 27.78)	25.83 (23.86, 28.04)	0.591
Risk factors, n (%)				
Cigarette smoking	292 (60.71)	297 (60.61)	309 (61.80)	0.913
Diabetes	181 (37.63)	210 (42.86)	222 (44.40)	0.080
Hypertension	290 (60.29)	328 (66.94)	337 (67.40)	0.034
Dyslipidemia	181 (37.63)	210 (42.86)	222 (44.40)	0.080
Prior PCI	139 (28.90)	143 (29.18)	158 (31.60)	0.595
PAD	61 (12.68)	72 (14.69)	67 (13.40)	0.650
Clinical presentations				
Multi-vessel CAD, n (%)	374 (77.75)	394 (80.41)	421 (84.20)	0.036
Median LVEF, % (IQR)	64 (62, 66)	64 (60, 66)	64 (60, 66)	0.095
Laboratory measurements				
WBC, 10 ⁹ /l (mean ± SD)	6.64±1.72	6.65±1.55	6.80±1.79	0.228
Neutrophil, 10 ⁹ /l (mean ± SD)	4.28±1.44	4.25±1.21	4.31±1.47	0.786
Lymphocyte, 10 ⁹ /l (mean ± SD)	1.85±0.57	1.83±0.61	1.90±0.62	0.179
Monocyte, 10 ⁹ /l (mean ± SD)	0.39±0.14	0.38±0.12	0.40±0.14	0.019
TC, mmol/l (mean ± SD)	4.04±0.98	4.00±1.04	4.13±1.09	0.135
LDL-C, mmol/l (mean ± SD)	2.35±0.82	2.36±0.85	2.51±0.88	0.004
HDL-C, mmol/l (mean ± SD)	1.28±0.35	1.06±0.24	0.97±0.23	<0.001
Triglycerides, mmol/l (mean ± SD)	1.43±0.75	1.85±1.34	2.00±1.39	<0.001
HbA1c, % (mean ± SD)	6.17±1.06	6.40±1.24	6.56±1.26	<0.001
Median eGFR, ml/min per 1.73m ² (IQR)	111.84 (98.60, 126.85)	111.55 (99.22, 124.69)	109.51 (94.63, 125.73)	0.182
hs-CRP, mg/l (mean ± SD)	1.50±0.51	2.49±0.68	7.96±8.77	<0.001
Medications at discharge, n (%)				
DAPT	480 (99.79)	490 (100.00)	498 (99.60)	0.378
Statins	474 (98.54)	481 (98.16)	486 (97.20)	0.306
ACEI/ARBs	203 (42.20)	252 (51.43)	281 (56.20)	<0.001
β-blockers	381 (79.21)	408 (83.27)	447 (89.40)	<0.001
Angiographic findings				
Target vessel territory				
LM, n (%)	14 (2.91)	11 (2.24)	19 (3.80)	0.354
LAD, n (%)	269 (55.93)	282 (57.55)	273 (54.60)	0.645
LCX, n (%)	118 (24.53)	125 (25.51)	125 (25.00)	0.940
RCA, n (%)	171 (35.55)	193 (39.39)	200 (40.00)	0.302
Restenotic lesions, n (%)	27 (5.61)	32 (6.53)	21 (4.20)	0.265
Trifurcation/bifurcation lesions, n (%)	257 (53.43)	262 (53.47)	282 (56.40)	0.560
Lesions>20 mm long, n (%)	311 (64.66)	353 (72.04)	374 (74.80)	0.002
Median number of stents (IQR)	2 (1, 2)	2 (1, 2)	2 (1, 2)	0.263
Median length of stent, mm (IQR)	28 (18, 46)	33 (21, 47)	33 (23, 49)	0.037
TIMI grade 0/1, n (%)	77 (16.01)	84 (17.14)	102 (20.40)	0.175

ACEI, angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blockers; BMI, body mass index; CAD, coronary artery disease; CHR, CRP-to-HDL ratio; DAPT, dual antiplatelet therapy; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein-cholesterol; HbA1c, glycated hemoglobin A1c; hs-CRP, hypersensitive C-reactive protein; IQR, interquartile range; LVEF, left ventricular ejection fraction; LDL-C, low-density lipoprotein-cholesterol; LM, left main coronary artery; LAD, left anterior descending coronary artery; LCX, left circumflex branch; PCI, percutaneous coronary intervention; PAD, peripheral arterial disease; RCA, right coronary artery; TC, total cholesterol; TIMI, thrombolysis in myocardial infarction; WBC, white blood cell.